NCT06092125 · RECRUITING
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
This trial is testing whether a combined PET/MR brain scan — a single imaging session that merges two types of scans — can improve early and accurate diagnosis across several major brain diseases, including Alzheimer's and Parkinson's. It is an observational imaging study with no phase designation, meaning it is not testing a drug or treatment but rather evaluating a diagnostic tool in real patients already receiving inpatient care.
You may qualify if
- Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines.
- Patients admitted to our hospital for inpatient treatment.
You're excluded if
- Patients who have undergone non-invasive/minimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month.
- Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination.
- patients with poorly controlled blood sugar and ineffective medication intervention.
- Patients with absolute contraindications for PET/MR examination.
- Karnofsky Performance Score (KPS) \<60.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-16